Ro launches GLP-1 supply tracker to address shortage of weight loss and diabetes drugs

From CNBC: 2024-05-29 09:55:24

Ro, a telehealth company, has unveiled a new GLP-1 supply tracker to help patients access weight loss and diabetes drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Ozempic amid U.S. shortages. The tracker provides real-time information on drug availability, dose sizes, and pharmacy locations, aiming to address the national healthcare crisis of GLP-1 shortages.

Anyone, including doctors, can report GLP-1 availability or shortages at specific pharmacies on Ro’s tracker. Updates are based on user submissions, FDA data, and Ro’s own patient supply information. By providing real-time data to the FDA, Ro hopes doctors can make informed medication choices, reducing disruptions in patient treatment.

Ro, previously known as Roman, launched the Ro Body Program in response to the high demand for GLP-1 medications like Ozempic and Wegovy. The company also offers compounded GLP-1s as alternatives when branded versions are scarce. Ro understands the challenges posed by drug shortages and hopes the tracker will ease supply issues and improve patient access to GLP-1 medications as demand continues to rise.



Read more at CNBC: Ro launches GLP-1 supply tracker to help patients navigate shortages